Clinical trials: Patients With Diabetes.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
Evaluate the efficacy, safety and tolerability of a 12-week treatment of 4 doses of ASP1941 compared to placebo in combination with metformin in adult patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on…
- Trial name
- BALANCE (NCT01117584)
- Testing
- ipragliflozin, Metformin
- Where
- 44 sites in United States, Hungary and 4 more
- Volunteers
- 343 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus
Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.
- Trial name
- NCT00762684
- Testing
- TAK-559
- Volunteers
- 8 people
- Sponsor
- Takeda
Type 2 Diabetes
Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes
This is a cross-sectional study planned among patients with Type 2 Diabetes (T2D) and Health Care Providers (HCPs) who treat T2D patients.
- Trial name
- NCT06517784
- Testing
- No treatment given
- Where
- India
- Volunteers
- 752 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
Diabetic Nephropathy
Effect of Sulodexide in Early Diabetic Nephropathy
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
- Trial name
- NCT00130208
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Keryx Biopharmaceuticals
Diabetic Macular Edema
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy
- Trial name
- NCT00665106
- Testing
- NOVA63035 "Corticosteroid"
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen SAS
Diabetes Mellitus, Type 2
Digital Diabetes Remission Trial
This is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered…
- Trial name
- DIGEST (NCT05647226)
- Testing
- Digital therapeutic and intensive lifestyle programme, Standard of care
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Habitual Health Ltd
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM) Secondary Objectives: To compare…
- Trial name
- Pen Preference (NCT01226043)
- Testing
- Insulin Glargine
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Sanofi
Type 2 Diabetes
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to…
- Trial name
- LixiLan-O (NCT02058147)
- Testing
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 273 sites in United States, Australia and 21 more
- Volunteers
- 1,170 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the the current status of diabetes management, control, and complications in diabetic subjects with type 2 diabetes in Bangladesh.
- Trial name
- DiabCare Asia (NCT01877200)
- Testing
- No treatment given
- Where
- Bangladesh
- Volunteers
- 2,092 people
- Sponsor
- Novo Nordisk A/S
Macular Edema
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
- Trial name
- DRAKO (NCT02850263)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer
Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers
This is a phase II single-blinded study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to standard therapy.
- Trial name
- NCT02619877
- Testing
- ALLO-ASC-DFU, Standard therapy
- Where
- 4 sites in South Korea
- Volunteers
- 59 people
- Sponsor
- Anterogen Co., Ltd.
Diabetes Mellitus
Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes
The purpose of this study is to evaluate two levels of the herbal extract Salacia oblonga (salacinol) on postprandial glycemia and insulinemia in patients with Type 2 diabetes after ingestion of a high-carbohydrate control meal.
- Trial name
- NCT00306072
- Testing
- nutritional herbal extract from Salacia oblonga
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Ross Products
Diabete Mellitus
Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes
This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT07229534
- Testing
- DA-5218, DA-5218-C
- Volunteers
- 238 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetic Foot Ulcer
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial…
- Trial name
- NCT00765063
- Testing
- Fragmin
- Where
- 27 sites in Austria, Belgium and 12 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral…
- Trial name
- NCT00242372
- Testing
- Tesaglitazar 0.5, Insulin at least 30 units/day
- Where
- 71 sites in United States
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors…
- Trial name
- NCT07156539
- Testing
- HS-20094 Injection, Dulaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes Mellitus
Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the long-term safety of TAK-559, once daily (QD), in subjects with Type 2 Diabetes.
- Trial name
- NCT00762112
- Testing
- TAK-559
- Volunteers
- 316 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.